Literature DB >> 33790974

Astragali Radix Contributes to the Inhibition of Liver Fibrosis via High-Mobility Group Box 1-Mediated Inflammatory Signaling Pathway.

Jianxia Wen1,2, Dan Wang1,2,3, Jian Wang2, Ruilin Wang4, Shizhang Wei1,2, Yanling Zhao1.   

Abstract

Astragali Radix (AR), the dried root of Astragali Radix membranaceus (Fisch.) Bge. or Astragali Radix membranaceus (Fisch.) Bge. var. mongholicus (Bge) Hsiao, is a commonly used traditional Chinese medicine for the treatment of liver diseases. This study aimed to comprehensively evaluate the pharmacological action and explore the potential mechanism of AR on liver fibrosis. Rats were administered with carbon tetrachloride for eight weeks, followed by oral treatment with AR for six weeks. The efficacy was confirmed by measuring liver function and liver fibrosis levels. The underlying mechanisms were explored by detecting the expression of related proteins. AR significantly decreased the serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), collagen IV (COL-IV), hyaluronic acid (HA), laminin (LN), and precollagen type III (PCIII). In addition, AR inhibited the deposition of collagen and the activation of hepatic stellate cells. Those data strongly demonstrated that AR alleviated liver fibrosis by CCl4. In order to illustrate the potential inflammatory, the mRNA levels of IL-6, TNF-α, and IL-1β were detected. Subsequently, immunohistochemistry analysis was performed to further verify the expression of type I collagen. Finally, the expression of key proteins in the inflammatory signaling pathway was detected. AR significantly reduced the expression of high-mobility group box 1 (HMGB1), TLR4, Myd88, RAGE, and NF-κ B p65 genes and proteins. In addition, western blotting showed AR decreased the protein expression of RAGE, p-MEK1/2, p-ERK1/2, and p-c-Jun. Taken together, our data reveal that AR significantly inhibits liver fibrosis by intervening in the HMGB1-mediated inflammatory signaling pathway and secretion signaling pathway. This study will provide valuable references for the in-depth research and development of Astragali Radix against liver fibrosis.
Copyright © 2021 Jianxia Wen et al.

Entities:  

Year:  2021        PMID: 33790974      PMCID: PMC7984916          DOI: 10.1155/2021/5574010

Source DB:  PubMed          Journal:  Evid Based Complement Alternat Med        ISSN: 1741-427X            Impact factor:   2.629


  43 in total

1.  Compound Astragalus and Salvia miltiorrhiza extract inhibits cell proliferation, invasion and collagen synthesis in keloid fibroblasts by mediating transforming growth factor-β / Smad pathway.

Authors:  S He; Y Yang; X Liu; W Huang; X Zhang; S Yang; X Zhang
Journal:  Br J Dermatol       Date:  2011-12-05       Impact factor: 9.302

Review 2.  Review of the botanical characteristics, phytochemistry, and pharmacology of Astragalus membranaceus (Huangqi).

Authors:  Juan Fu; Zenghui Wang; Linfang Huang; Sihao Zheng; Dongmei Wang; Shilin Chen; Haitao Zhang; Shihai Yang
Journal:  Phytother Res       Date:  2014-08-02       Impact factor: 5.878

3.  Subchronic toxicity studies of Radix Astragali extract in rats and dogs.

Authors:  Shu-Yi Yu; Hong-Tao Ouyang; Ju-Yun Yang; Xiao-Liang Huang; Ting Yang; Ju-Ping Duan; Jun-Ping Cheng; Yu-Xiang Chen; Yong-Jia Yang; Pang Qiong
Journal:  J Ethnopharmacol       Date:  2006-09-27       Impact factor: 4.360

Review 4.  Antifibrotic Therapies: Where Are We Now?

Authors:  Young Joon Yoon; Scott L Friedman; Youngmin A Lee
Journal:  Semin Liver Dis       Date:  2016-02-12       Impact factor: 6.115

5.  Anthocyanins isolated from blueberry ameliorates CCl4 induced liver fibrosis by modulation of oxidative stress, inflammation and stellate cell activation in mice.

Authors:  Jianchao Sun; Yafeng Wu; Cuizhen Long; Ping He; Junying Gu; Lei Yang; Yaodong Liang; Yuping Wang
Journal:  Food Chem Toxicol       Date:  2018-07-27       Impact factor: 6.023

6.  Differential regulation of c-Jun by ERK and JNK during PC12 cell differentiation.

Authors:  S Leppä; R Saffrich; W Ansorge; D Bohmann
Journal:  EMBO J       Date:  1998-08-03       Impact factor: 11.598

7.  High Mobility Group Box-1 Drives Fibrosis Progression Signaling via the Receptor for Advanced Glycation End Products in Mice.

Authors:  Xiaodong Ge; Elena Arriazu; Fernando Magdaleno; Daniel J Antoine; Rouchelle Dela Cruz; Neil Theise; Natalia Nieto
Journal:  Hepatology       Date:  2018-11-13       Impact factor: 17.425

8.  Huang-Qi San improves glucose and lipid metabolism and exerts protective effects against hepatic steatosis in high fat diet-fed rats.

Authors:  Yan Li; Chunyi Wang; Yu Jin; Haibo Chen; Meiqun Cao; Weimin Li; Huanmin Luo; Zhengzhi Wu
Journal:  Biomed Pharmacother       Date:  2020-02-27       Impact factor: 6.529

Review 9.  Danger-Associated Molecular Patterns (DAMPs): Molecular Triggers for Sterile Inflammation in the Liver.

Authors:  Sabine Mihm
Journal:  Int J Mol Sci       Date:  2018-10-10       Impact factor: 5.923

Review 10.  Crosstalk network among multiple inflammatory mediators in liver fibrosis.

Authors:  Han-Jing Zhangdi; Si-Biao Su; Fei Wang; Zi-Yu Liang; Yu-Dong Yan; Shan-Yu Qin; Hai-Xing Jiang
Journal:  World J Gastroenterol       Date:  2019-09-07       Impact factor: 5.742

View more
  1 in total

1.  Study on the Anti-Inflammatory Effect and Mechanism of Yuxuebi Tablet Based on Network Pharmacology.

Authors:  Xiangka Hu; Ping Shao; Xiaojuan Liu; Ling Han; Liuming Gui; Zengxiaorui Cai; Mushuang Qi; Chunmei Dai
Journal:  ACS Omega       Date:  2022-08-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.